ArticleCancer management and research2019
Incidence, risk factors, and prognosis in patients with primary hepatocellular carcinoma and lung metastasis: a population-based study.
Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07482670 (Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases), which is not on this map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases (CAPLocal) : A Multicentre, Single-Arm,Prospective Cohort Study
Who cites it
31 citing papers in PubMed, 45 citations in OpenAlex.
- The Thoracic Footprint of Hepatocellular Carcinoma: A Mechanism-Based Imaging Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- Sleeve Resection of the Right Upper Lobe for Tracheobronchial Metastasis of Hepatocellular Carcinoma With Superior Vena Cava Involvement: A Case Report and Literature Review.The American journal of case reports · 2026Review
- Signalling pathways in hepatocellular carcinoma (HCC) metastasis and invasion: Molecular mechanisms and therapeutic implications.Biochemistry and biophysics reports · 2026Review
- Safety and Efficacy of TACE Sequential Thermal Ablation in the Treatment of Hepatocellular Carcinoma After TIPS.Journal of hepatocellular carcinoma · 2026Article
- Inhibiting B cells enhances the efficacy of STING agonism or immune checkpoint blockade in hepatocellular carcinoma.Nature communications · 2025Article
- Review
- Article
- Carbon-Ion Radiotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects: A Narrative Review.Journal of clinical medicine · 2025Review
- Lung metastases.Nature reviews. Disease primers · 2025Review
- Development of a predictive model for lung metastasis in hepatocellular carcinoma patients: insights from SEER database analysis.Updates in surgery · 2025Article
- Transcription Factor TCF12 Activates the Transcription Level of SLC38A1 to Promote the Development of Hepatocellular Carcinoma.Applied biochemistry and biotechnology · 2025Article
- lncRNAs as Biomarkers of Hepatocellular Carcinoma Risk and Liver Damage in Advanced Chronic Hepatitis C.Current issues in molecular biology · 2025Article
- Case Report: Durable complete response of advanced-stage hepatocellular carcinoma to DEB-TACE combined with lenvatinib and camrelizumab.Frontiers in immunology · 2025Article
- Pathological complete response after conversion therapy in unresectable hepatocellular carcinoma: a retrospective study.BMC gastroenterology · 2024Article
- Prognostic Factors of Pulmonary Metastasectomy for Oligometastatic Hepatocellular Carcinoma Spread to the Lungs.Journal of clinical medicine · 2024Article
- Comparison of metastasis and prognosis between early-onset and late-onset hepatocellular carcinoma: A population-based study.Heliyon · 2024Article
- OHCCPredictor: an online risk stratification model for predicting survival duration of older patients with hepatocellular carcinoma.Hepatology international · 2024Article
- A hsa_circ_001726 axis regulated by E2F6 contributes to metastasis of hepatocellular carcinoma.BMC cancer · 2024Article
- Sintilimab Plus Lenvatinib with or Without Radiotherapy for Advanced Hepatocellular Carcinoma with Pulmonary Metastasis.Journal of hepatocellular carcinoma · 2024Article
- Predictors of survival among patients with chronic hepatitis C at a tertiary care center in Oman.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe study aims to explore the incidence, risk factors, and prognosis in patients with primary hepatocellular carcinoma (HCC) and synchronous lung metastasis using a large-scale population-based cancer registry database. PATIENTS AND
methodsData of 33,177 HCC patients were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015. Multivariate logistic and Cox regression model analysis were applied for the recognition of risk factors and prognostic factors associated with lung metastasis among HCC patients. The overall survival and cancer-specific survival of HCC patients with initial pulmonary metastasis were estimated by Kaplan- Meier analysis, and the survival curves were compared by log-rank tests.
resultsTotal 2,084 (6.28%) HCC patients diagnosed with initial pulmonary metastasis were enrolled for analysis. Male gender, younger age, non-white race, unmarried status, uninsured status, elevated alpha-fetoprotein, larger primary liver tumor size, positive lymph node status, synchronal bone or brain metastasis, and tumor poor pathological differentiation were relevant to higher risk of lung metastasis in HCC cohort. The 1-, 3-, 5-year overall survival and cancer-specific survival rates for HCC lung metastasis patients were 12.8% vs 15.3%, 4.0% vs 5.7%, and 1.6% versus 2.4%, respectively. The median overall and cancer-specific survival time in HCC lung metastasis group were both 3 months, while the corresponding time in HCC lung metastasis-free group were 19 and 25 months (
conclusionThe survival of patients with HCC lung metastasis was dismal. Several clinicopathological factors were found to be significantly relevant to the development and prognosis of HCC lung metastasis. These new findings could be useful for a precise and individualized therapeutic schedule.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.